Difficidin and oxydifficidin, two novel macrocyclic polyene lactone phosphate esters were discovered in fermentation broths of each of two strains of Bacillus subtilis: ATCC 39320 and ATCC39374. Difficidin and oxydifficidin each showed a broad spectrum of activity against aerobic and anaerobic bacteria. Manyof the susceptible aerobes and anaerobes were humanpathogens resistant to one or more antibiotics. Difficidin and oxydifficidin when administered intraperitoneally protected mice against an otherwise lethal bacteremia caused by Klebsiella pneumoniae (ED50 in mg/kg of 1.31 and 15.6 respectively).
In the course of screening for new antibiotics, difficidin and oxydifficidin, two novel macrocyclic polyene lactone phosphate esters0, (Fig. 1) were discovered in fermentation broths of each of two strains of Bacillus subtilis:
ATCC 39320 and ATCC39374. Bacillin2) was also isolated from fermentation broths of each strain.
Difficidin and oxydifficidin demonstrated broad and potent activities in vitro against aerobic and anaerobic bacteria, manyof which are human pathogens that are resistant to one or more antibiotics. Both antibiotics were active in vivo whenadministered via the intraperitoneal route, but not via the subcutaneous route, to mice infected with Klebsiella pneumoniae. Mode of action studies3) indicate that difficidin is bactericidal and acts by inhibiting protein synthesis. A portion of this work was presented at the 26th Intersci. Conf. on Antimicrob. Agents Chemother., New Orleans, Sept. 28~Oct. 1, 1986.
Fermentation THE JOURNAL OF ANTIBIOTICS
Materials and Methods DEC. 1987 "A" Stage: Culture ATCC39320 is maintained in the lyophilized state in a 1.0-ml ampule containing 0.15 ml of a skim milk suspension of the culture. "B" Stage: Vessel; 250-ml 3-baffled Erlenmeyer flask containing 50 ml of medium per flask. Medium; glucose 1 g/liter, soluble starch lO g/liter, beef extract 3 g/liter, Ardamine pH 5 g/liter, NZ-Amine type E 5 g/liter, MgSO4-7H2O 0.05 g/liter, 1.34 m phosphate buffer (KH2PO4 91 g/liter, Na2HPO4 95 g/liter) 0.02%, CaCO3 (after pH adjustment to 7.0-7.2) 0.05%, distilled water 1,000 ml. Inoculum; contents of one lyophilization tube into each "B" flask. Incubation; 24 hours at 28°C on a rotary shaker with a 5 cm-throw at 220 rpm. "C" Stage: Vessel; 250-ml Erlenmeyer flasks containing 40 ml of medium. 
Antibacterial Activity In Vitro
Aerobic Bacteria: MICsfor aerobic strains of bacteria were determined in agar dilution assays. Cultures were inoculated from stock slants prepared from cultures stored in the Merck Culture Collection (designated as MBnumbers), incubated in Trypticase soy broth at 35°C for 18 hours and applied to the surface of medicated Trypticase soy agar with a Denley Multipoint Inoculator at an inoculumof 106 cfu/spot. The susceptibility plates were medicated with aqueous solution of antibiotic. Difficidin and oxydifficidin test samples of >90 % purity were prepared as described by Wilson et alP. Cefoxitin sodium (Mefoxin) and streptomycin sulfate were used as a control for comparing MICs. Assay plates were incubated at 35°C for 20-24 hours. Endpoints were read to <5 discrete colonies.
Anaerobic Bacteria : MICsof strains of anaerobic bacteria were determined in agar dilution assays in a manner similar to that described for aerobic bacteria, except for the following differences: (1) Wilkins-Chalgren agar was used as the assay medium; (2) assay plates were incubated for 44 hours under anaerobic conditions.
Antibacterial Activity In Vivo
The therapeutic efficacy of difficidin and oxydifficidin was determined in standard mouseprotection tests. An experimental systemic infection was produced in CD1female mice (Charles River Breeding Lab., Wilmington, MA) by the intraperitoneal injection of a suitably diluted broth culture of K, pneumoniae (MB4005 in the Merck Culture Collection). The test antibacterial compounds and the control drug (streptomycin sulfate) were administered parenterally (intraperitoneally or subcutaneously) immediately after infection and again 6 hours later. At least 4-fold dilutions of each agent were tested. There were 5 mice at each dose level. All mice were observed for a period of 7 days after which the median effective dose (ED50) was calculated by the method of Knudsen and Curtis6) . Under the conditions of the test, all infected untreated mice died within 48 hours.
Results

Fermentation
Fermentation yields were 270 /Wml for difficidin and 160^g/ml for oxydifficidin. Purification procedures0 resulted in isolation of material of >90 % purity for use in all antibiotic testing. subtilis.
Morphological and Physiological Characteristics of B. subtilis ATCC39374
The morphological and physiological properties of ATCC39374 are the same as those indicated above for ATCC39320, except with respect to the appearance of the colonies of the microorganism, which are as follows.
Colonial Appearance: At 24 hours, raised, round, mucoid. As colony ages, edge becomes dry, opaque and irregular. Central mucoid area continues to dry, becoming opaque and wrinkled. Dull, wrinkled entire pellicle on surface of broth. No pigmentation on Trypticase soy agar. Growth at 28°C, 37°C, no growth at 60°C.
Antibacterial
Activity vs. Aerobes Table 1 demonstrates that difficidin has a broad spectrum of activity against aerobic bacteria, with MICs of 0.5~16 jug/ml except for Streptococcus faecalis (>128 jug/ml). Difficidin MICs were generally 2~8 x lower for a majority of the strains than those of oxydifficidin. Difficidin was superior to cefoxitin vs. Proteus sp., one strain of methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa and Serratia marcescens. Difficidin was superior to streptomycin vs. S. aureus, Proteus sp., Salmonella typhimurium, P. aeruginosa and S. marcescens.
Activity vs. Anaerobic bacteria Against anaerobes (Table 2) , difficidin and oxydifficidin each demonstrated a broad spectrum, particularly against strains of Clostridium difficile, Bacteroides sp. and Fusobacterium mortiferum. Antibacterial Activity In Vivo The data in Table 3 show that when administered intraperitoneally, difficidin and oxydifficidin were effective in protecting mice against an otherwise lethal infection of K. pneumoniae MB4005 (ED50 of 1.31 and 15.6 mg/kg respectively). Neither antibiotic was effective when administered via the subcutaneous route. The drugs were not toxic at the levels tested.
Discussion
Difficidin and oxydifficidin are novel broad spectrum antibacterial antibiotics which demonstrated excellent in vitro activity against both aerobic and anaerobic strains of bacteria, many of which are pathogenic to humans. Both antibiotics when administered intraperitoneally protected mice against an experimental K. pneumoniae bacteremia. The inability to demonstrate in vivo activity via the subcutaneous route suggests that difficidin and oxydifficidin are metabolized and/or are not reaching the site of infection in time to prevent it.
